PUBLICATIONS

Circulation Research – Intravenously-Delivered Mesenchymal Stem Cells: Systemic Anti-Inflammatory Effects Improve Left Ventricular Dysfunction in Acute Myocardial Infarction and Ischemic Cardiomyopathy

Abstract Rationale: Virtually all mesenchymal stem cell (MSC) studies assume therapeutic effects accrue from local myocardial effects of engrafted MSCs. Since few intravenously-administered MSCs engraft in the myocardium, studies have mainly utilized direct myocardial...

Circulation Research, a Journal of the American Heart Association – Intravenous Allogeneic Mesenchymal Stem Cells for Non-Ischemic Cardiomyopathy: Safety and Efficacy Results of a Phase II-A Randomized Trial

Potential benefits of mesenchymal stem cell (MSC) therapy in heart failure (HF) may be related to paracrine properties and systemic effects, including anti-inflammatory activities. If this hypothesis is valid, intravenous administration of MSCs should improve outcomes in HF, an entity in which excessive chronic inflammation may play a pivotal role.